653 related articles for article (PubMed ID: 16836561)
1. Removal of small nonenveloped viruses by antibody-enhanced nanofiltration during the manufacture of plasma derivatives.
Kreil TR; Wieser A; Berting A; Spruth M; Medek C; Pölsler G; Gaida T; Hämmerle T; Teschner W; Schwarz HP; Barrett PN
Transfusion; 2006 Jul; 46(7):1143-51. PubMed ID: 16836561
[TBL] [Abstract][Full Text] [Related]
2. Removal of small non-enveloped viruses by nanofiltration.
Yokoyama T; Murai K; Murozuka T; Wakisaka A; Tanifuji M; Fujii N; Tomono T
Vox Sang; 2004 May; 86(4):225-9. PubMed ID: 15144526
[TBL] [Abstract][Full Text] [Related]
3. [Evaluation of the virus-elimination efficacy of nanofiltration (Viresolve NFP) for the parvovirus B19 and hepatitis A virus].
Oh DJ; Lee YL; Kang JW; Kwon SY; Cho NS; Kim IS
Korean J Lab Med; 2010 Feb; 30(1):45-50. PubMed ID: 20197722
[TBL] [Abstract][Full Text] [Related]
4. Inactivation of parvovirus B19 during STIM-4 vapor heat treatment of three coagulation factor concentrates.
Berting A; Modrof J; Unger U; Gessner M; Klotz A; Poelsler G; Kreil TR
Transfusion; 2008 Jun; 48(6):1220-6. PubMed ID: 18410254
[TBL] [Abstract][Full Text] [Related]
5. Removal of neutralized model parvoviruses and enteroviruses in human IgG solutions by nanofiltration.
Omar A; Kempf C
Transfusion; 2002 Aug; 42(8):1005-10. PubMed ID: 12385411
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of nanofiltration in removing small non-enveloped viruses from three different plasma-derived products.
Menconi MC; Maggi F; Zakrzewska K; Salotti V; Giovacchini P; Farina C; Andreoli E; Corcioli F; Bendinelli M; Azzi A
Transfus Med; 2009 Aug; 19(4):213-7. PubMed ID: 19706139
[TBL] [Abstract][Full Text] [Related]
7. Different behavior of erythrovirus B19 and torquetenovirus in response to a single step of albumin purification.
Azzi A; Maggi F; Zakrzewska K; Menconi MC; Di Pietro N; Salotti V; Farina C; Andreoli E; Fiorentino B; Angelini C; Corcioli F; Bendinelli M
Transfusion; 2006 Jul; 46(7):1162-7. PubMed ID: 16836563
[TBL] [Abstract][Full Text] [Related]
8. Pathogen safety of intravenous Rh immunoglobulin liquid and other immune globulin products: enhanced nanofiltration and manufacturing process overview.
Soluk L; Price H; Sinclair C; Atalla-Mikhail D; Genereux M
Am J Ther; 2008; 15(5):435-43. PubMed ID: 18806519
[TBL] [Abstract][Full Text] [Related]
9. Implementation of a 20-nm pore-size filter in the plasma-derived factor VIII manufacturing process.
Furuya K; Murai K; Yokoyama T; Maeno H; Takeda Y; Murozuka T; Wakisaka A; Tanifuji M; Tomono T
Vox Sang; 2006 Aug; 91(2):119-25. PubMed ID: 16907872
[TBL] [Abstract][Full Text] [Related]
10. Different susceptibility of B19 virus and mice minute virus to low pH treatment.
Boschetti N; Niederhauser I; Kempf C; Stühler A; Löwer J; Blümel J
Transfusion; 2004 Jul; 44(7):1079-86. PubMed ID: 15225251
[TBL] [Abstract][Full Text] [Related]
11. Viral safety of Nanogam, a new 15 nm-filtered liquid immunoglobulin product.
Terpstra FG; Parkkinen J; Tölö H; Koenderman AH; Ter Hart HG; von Bonsdorff L; Törmä E; van Engelenburg FA
Vox Sang; 2006 Jan; 90(1):21-32. PubMed ID: 16359352
[TBL] [Abstract][Full Text] [Related]
12. Removal of viruses from human intravenous immune globulin by 35 nm nanofiltration.
Troccoli NM; McIver J; Losikoff A; Poiley J
Biologicals; 1998 Dec; 26(4):321-9. PubMed ID: 10403036
[TBL] [Abstract][Full Text] [Related]
13. Neutralization of human parvovirus B19 by plasma and intravenous immunoglobulins.
Modrof J; Berting A; Tille B; Klotz A; Forstner C; Rieger S; Aberham C; Gessner M; Kreil TR
Transfusion; 2008 Jan; 48(1):178-86. PubMed ID: 17900278
[TBL] [Abstract][Full Text] [Related]
14. Multicenter evaluation of a commercial multiplex polymerase chain reaction test for screening plasma donations for parvovirus B19 DNA and hepatitis A virus RNA.
Koppelman MH; Cuijpers HT; Wessberg S; Valkeajärvi A; Pichl L; Schottstedt V; Saldanha J
Transfusion; 2012 Jul; 52(7):1498-508. PubMed ID: 22587637
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of nucleic acid sequences specific for human parvoviruses, hepatitis A and hepatitis E viruses in coagulation factor concentrates.
Modrow S; Wenzel JJ; Schimanski S; Schwarzbeck J; Rothe U; Oldenburg J; Jilg W; Eis-Hübinger AM
Vox Sang; 2011 May; 100(4):351-8. PubMed ID: 21133933
[TBL] [Abstract][Full Text] [Related]
16. Nanofiltration as a robust method contributing to viral safety of plasma-derived therapeutics: 20 years' experience of the plasma protein manufacturers.
Roth NJ; Dichtelmüller HO; Fabbrizzi F; Flechsig E; Gröner A; Gustafson M; Jorquera JI; Kreil TR; Misztela D; Moretti E; Moscardini M; Poelsler G; More J; Roberts P; Wieser A; Gajardo R
Transfusion; 2020 Nov; 60(11):2661-2674. PubMed ID: 32815181
[TBL] [Abstract][Full Text] [Related]
17. Safety issues for plasma derivatives and benefit from NAT testing.
Willkommen H; Schmidt I; Löwer J
Biologicals; 1999 Dec; 27(4):325-31. PubMed ID: 10686059
[TBL] [Abstract][Full Text] [Related]
18. Improvement of virus safety of an antihemophilc factor IX by virus filtration process.
Kim IS; Choi YW; Kang Y; Sung HM; Sohn KW; Kim YS
J Microbiol Biotechnol; 2008 Jul; 18(7):1317-25. PubMed ID: 18667862
[TBL] [Abstract][Full Text] [Related]
19. Scrapie removal using Planova virus removal filters.
Tateishi J; Kitamoto T; Mohri S; Satoh S; Sato T; Shepherd A; Macnaughton MR
Biologicals; 2001 Mar; 29(1):17-25. PubMed ID: 11482889
[TBL] [Abstract][Full Text] [Related]
20. Robustness of nanofiltration for increasing the viral safety margin of biological products.
Caballero S; Diez JM; Belda FJ; Otegui M; Herring S; Roth NJ; Lee D; Gajardo R; Jorquera JI
Biologicals; 2014 Mar; 42(2):79-85. PubMed ID: 24485384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
